Patenting perspective on Keap1 inhibitors (2019-2024)

被引：0
|
作者：
Luo, Yongfu [1 ]
Yang, Ziyu [1 ]
Zhang, Yuan [1 ]
Jiang, Shutong [1 ]
Zhu, Jingyu [1 ]
Li, Xiangyang [1 ,2 ]
You, Qidong [1 ,3 ,4 ,5 ]
Lu, Mengchen [1 ]
机构：
[1] Soochow Univ, Coll Pharmaceut Sci, Med Coll, Dept Med Chem, Suzhou 215123, Peoples R China
[2] Microcell Pharmaceut Suzhou Co Ltd, Dept Res & Dev, Suzhou, Peoples R China
[3] China Pharmaceut Univ, Jiangsu Key Lab Drug Design & Optimizat, TongJiaXiang 24, Nanjing 210009, Peoples R China
[4] China Pharmaceut Univ, State Key Lab Nat Med, TongJiaXiang 24, Nanjing 210009, Peoples R China
[5] China Pharmaceut Univ, Nanjing 211198, Peoples R China
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 2025年 / 35卷 / 04期
基金：
中国国家自然科学基金;
关键词：
Keap1; Nrf2; oxidative stress; electrophilic inhibitors; protein-protein interaction inhibitors; PROTEIN-PROTEIN INTERACTION; FUMARIC-ACID ESTERS; OXIDATIVE STRESS; DIMETHYL FUMARATE; MULTIPLE-SCLEROSIS; KELCH DOMAIN; NRF2; PATHWAY; ACTIVATION; BINDING; REDOX;
D O I：
10.1080/13543776.2025.2462844
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
IntroductionKelch-like ECH-associated protein 1 (Keap1), an E3 ligase negatively regulating the nuclear factor erythroid 2-related factor 2 (Nrf2), has emerged as an auspicious drug target for treating ailments associated with oxidative stress and inflammation. Discovery of Keap1 inhibitors have attracted significant interest. Areas coveredThis review covers patents on Keap1 inhibitors from 2019 to 2024, providing a comprehensive analysis of their structural characteristics, optimization strategies, pharmacological properties and clinical progress. Expert opinionExtensive efforts have been devoted to enhance potency and drug-like properties of Keap1 inhibitors. Strategies such as ROS-cleavable prodrug design, bivalent inhibition and PROTACs are emerging. As the range of drug types and applications expands, Keap1 inhibitors are becoming a sagacious option for disease treating.
引用
收藏
页码：325 / 356
页数：32
相关论文
共 50 条
  • [31] Synthesis and Evaluation of Noncovalent Naphthalene-Based KEAP1-NRF2 Inhibitors
    Lazzara, Phillip R.
    Jain, Atul D.
    Maldonado, Amanda C.
    Richardson, Benjamin
    Skowron, Kornelia J.
    David, Brian P.
    Siddiqui, Zamia
    Ratia, Kiira M.
    Moore, Terry W.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (04): : 521 - 527
  • [32] Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy
    Zhang, Jingze
    Jiao, Qinghua
    Kong, Li
    Yu, Jing
    Fang, Aiju
    Li, Minghuan
    Yu, Jinming
    THORACIC CANCER, 2018, 9 (06) : 726 - 735
  • [33] The effect of curcumin on NRF2/Keap1 signalling pathway in the epididymis of mouse experimental cryptorchidism
    Hemati, Uosef
    Moshajari, Minoo
    Mashayekhi, Farideh Jalali
    Bayat, Mohammad
    Moslemi, Azam
    Baazm, Maryam
    ANDROLOGIA, 2022, 54 (10)
  • [34] Bis-Michael Acceptors as Novel Probes to Study the Keap1/Nrf2/ARE Pathway
    Deny, Ludovic J.
    Traboulsi, Hussein
    Cantin, Andre M.
    Marsault, Eric
    Richter, Martin V.
    Belanger, Guillaume
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (20) : 9431 - 9442
  • [35] Covalent Inhibitors of KEAP1 with Exquisite Selectivity
    Fejes, Imre
    Markacz, Piroska
    Tatai, Janos
    Rudas, Monika
    Dunkel, Petra
    Gyuris, Mario
    Nyerges, Miklos
    Provost, Nicolas
    Duvivier, Valerie
    Delerive, Philippe
    Martiny, Virginie
    Bristiel, Alexandra
    Vidal, Brice
    Richardson, William
    Rothweiler, Elisabeth M.
    Tranberg-Jensen, Jeppe
    Manning, Charlotte E.
    Sweeney, Melissa N.
    Chalk, Rod
    Huber, Kilian V. M.
    Bullock, Alex N.
    Herner, Andras
    Seedorf, Klaus
    Vinson, Cedric
    Weber, Csaba
    Kotschy, Andras
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (23) : 21208 - 21222
  • [36] Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation
    Gong, Meiling
    Li, Yan
    Ye, Xiaoping
    Zhang, Linlin
    Wang, Zhifang
    Xu, Xiaowen
    Shen, Yejing
    Zheng, Cuixia
    CELL COMMUNICATION AND SIGNALING, 2020, 18 (01)
  • [37] Keap1 modulates the redox cycle and hepatocyte cell cycle in regenerating liver
    Hu, Min
    Zou, Yuhong
    Nambiar, Shashank Manohar
    Lee, Joonyong
    Yang, Yan
    Dai, Guoli
    CELL CYCLE, 2014, 13 (15) : 2349 - 2358
  • [38] NRF2-Driven KEAP1 Transcription in Human Lung Cancer
    Tian, Yijun
    Liu, Qian
    Yu, Shengnan
    Chu, Qian
    Chen, Yuan
    Wu, Kongming
    Wang, Liang
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 1465 - 1476
  • [39] Modulation of Keap1/Nrf2/ARE Signaling Pathway by Curcuma- and Garlic-Derived Hybrids
    Serafini, Melania Maria
    Catanzaro, Michele
    Fagiani, Francesca
    Simoni, Elena
    Caporaso, Roberta
    Dacrema, Marco
    Romanoni, Irene
    Govoni, Stefano
    Racchi, Marco
    Daglia, Maria
    Rosini, Michela
    Lanni, Cristina
    FRONTIERS IN PHARMACOLOGY, 2020, 10
  • [40] Drug screening assay based on the interaction of intact Keap1 and Nrf2 proteins in cancer cells
    Zhou, Bo
    Zhang, Xiaolei
    Wang, Guiren
    Barbour, Karen W.
    Berger, Franklin G.
    Wang, Qian
    BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (01) : 92 - 99
12345